Scarica l'app Stockscreener
3.20
0.95%
0.03
Dopo l'orario di chiusura:
3.22
0.02
+0.63%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VTYX Giù?
Forum
Previsione
Precedente Chiudi:
$3.17
Aprire:
$3.17
Volume 24 ore:
1.16M
Relative Volume:
0.72
Capitalizzazione di mercato:
$227.72M
Reddito:
-
Utile/perdita netta:
$-192.96M
Rapporto P/E:
-0.9697
EPS:
-3.3
Flusso di cassa netto:
$-167.04M
1 W Prestazione:
-2.14%
1M Prestazione:
+32.78%
6M Prestazione:
+42.22%
1 anno Prestazione:
+12.68%
Intervallo 1D:
$3.15
$3.2999
Intervallo di 1 settimana:
$2.881
$3.3499
Portata 52W:
$0.783
$3.39
Ventyx Biosciences Inc Stock (VTYX) Company Profile
Nome
Ventyx Biosciences Inc
Settore
Industria
Telefono
(858) 945-2393
Indirizzo
12790 EL CAMINO REAL, SUITE 200, SAN DIEGO
Confronta VTYX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTYX
Ventyx Biosciences Inc
|
3.20 | 225.58M | 0 | -192.96M | -167.04M | -3.30 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Ventyx Biosciences Inc Stock (VTYX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-03-12 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2024-03-12 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-11-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2023-11-07 | Downgrade | Oppenheimer | Outperform → Perform |
| 2023-11-07 | Downgrade | Stifel | Buy → Hold |
| 2023-11-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-06-14 | Ripresa | Credit Suisse | Outperform |
| 2023-03-21 | Iniziato | Wells Fargo | Overweight |
| 2022-12-19 | Iniziato | Goldman | Buy |
| 2022-11-17 | Iniziato | Morgan Stanley | Overweight |
| 2022-09-07 | Iniziato | Stifel | Buy |
| 2022-09-01 | Iniziato | H.C. Wainwright | Buy |
| 2022-05-09 | Iniziato | Credit Suisse | Outperform |
| 2022-03-31 | Iniziato | Canaccord Genuity | Buy |
| 2022-02-01 | Iniziato | Oppenheimer | Outperform |
| 2021-11-15 | Iniziato | Jefferies | Buy |
| 2021-11-15 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Ventyx Biosciences Inc Borsa (VTYX) Ultime notizie
Is Ventyx Biosciences Inc. a good long term investmentUnrivaled growth potential - Autocar Professional
Ventyx Biosciences Inc. Stock Analysis and ForecastSuperior risk-adjusted returns - Autocar Professional
What analysts say about Ventyx Biosciences Inc. stockRecord-setting profit potential - jammulinksnews.com
Why Ventyx Biosciences Inc. stock attracts strong analyst attentionSmart Return Focused Trading - Newser
Is Ventyx Biosciences (NASDAQ:VTYX) In A Good Position To Invest In Growth? - Yahoo Finance
What drives Ventyx Biosciences Inc. stock priceFree Stock Market Real-Time Monitoring - jammulinksnews.com
What makes Ventyx Biosciences Inc. stock price move sharplyFree Insider Trading Tips - Newser
How Ventyx Biosciences Inc. stock performs during market volatilityAlpha Stock Ideas - Newser
Wealth Enhancement Advisory Services LLC Invests $28,000 in Ventyx Biosciences, Inc. (NASDAQ:VTYX) - Defense World
Ventyx Biosciences (VTYX) Upgraded to Strong Buy: What Does It Mean for the Stock? - Yahoo Finance
Analyzing the Impact of Earnings Reports on Ventyx Biosciences Inc Inc. (VTYX) Price Performance - investchronicle.com
Class Action Filed Against Ventyx Biosciences, Inc. (VTYX)April 30, 2024 Deadline to JoinContact Levi & Korsinsky - ACCESS Newswire
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Ventyx Biosciences, Inc. (VTYX) Shareholders - ACCESS Newswire
Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000E Index - MarketScreener
Ventyx Biosciences, Inc.(NasdaqGS: VTYX) dropped from Russell 3000 Value Index - MarketScreener
Ventyx Biosciences, Inc. (NASDAQ:VTYX) Shares Sold by Rhumbline Advisers - Defense World
Canaccord maintains buy rating on Ventyx stock after positive trial results - Investing.com
Ventyx stock steady as Parkinson’s drug shows biomarker reductions By Investing.com - Investing.com India
Ventyx reports positive outcomes from trial of VTX3232 for Parkinson’s - Yahoo Finance
Ventyx Therapeutics' VTX3232: A Neuroinflammation Breakthrough with Orphan Drug Pricing Power - AInvest
Ventyx Biosciences Inc’s Mixed Bag: Down -9.22% in 6 Months, Down 58.21% in 30 Days - investchronicle.com
Ventyx Biosciences Holds Steady Despite Encouraging Early Parkinson’s Trial Results - MSN
Ventyx Biosciences Announces Positive Top-Line Data from - GlobeNewswire
Ventyx Biosciences Shares Fall After Tier 2 Exploratory Biomarkers Remain Stable in Parkinson's Study - MarketScreener
Ventyx reports positive Phase 2a results for Parkinson’s drug - Investing.com
Ventyx Biosciences Insiders Placed Bullish Bets Worth US$1.26m - Yahoo.co
Ventyx Biosciences' Study of VTX3232 Met Safety, Tolerability Objectives - MarketWatch
Ventyx posts mid-stage trial win for Parkinson’s drug (VTYX) - Seeking Alpha
Ventyx Biosciences stock trades flat despite positive parkinson’s drug trial data - Investing.com Canada
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson'S Disease - marketscreener.com
Ventyx Biosciences Announces Positive Data From Its Phase 2A Trial Evaluating Vtx3232 In Patients With Early-Stage Parkinson’S Disease - TradingView
Ventyx reports positive Phase 2a results for Parkinson’s drug By Investing.com - Investing.com India
VTYX Trading Halted as Market Awaits News Update | VTYX Stock News - GuruFocus
Ventyx Biosciences Inc Azioni (VTYX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):